<DOC>
	<DOCNO>NCT02431754</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy study drug know tadalafil participant benign prostatic hyperplasia treat alpha1 blocker . This study two treatment period . Participants receive tadalafil placebo treatment period .</brief_summary>
	<brief_title>A Study Tadalafil ( LY450190 ) Participants With Lower Urinary Tract Symptoms ( LUTS ) Suggestive Benign Prostatic Hyperplasia LUTS ( BPH-LUTS ) .</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Present benign prostatic hyperplasia ( BPH ; also refer BPHLUTS ) , base disease diagnostic criterion , study entry . Have treat stable dose alpha1 blocker ( tamsulosin 0.2 mg daily silodosin 4 mg twice daily ) least 8 week prior screen , continue alpha1 blocker dose entire duration study . Are Japanese men . Have prostate volume ≥20 milliliter ( mL ) estimate transabdominal transrectal ultrasound screening . Have BPHLUTS Total International Prostate Symptom Score ( IPSS ) ≥12 screen baseline . Have moderate LUTS urinary peak flow rate ( Qmax ) ≥4 ≤15 mL/second baseline , meet follow criterion : Prevoid total bladder volume ≥150 ≤550 mL assess ultrasound Minimum void volume ≥125 mL Demonstrate ≥80 % compliance alpha1 blocker treatment* screen period , document baseline *Tamsulosin : ( Number dose take / Number day treat ) × 100 Silodosin : ( Number dose take / Number day treat ) × 50 Prostatespecific antigen ( PSA ) &gt; 10.0 nanogram ( ng ) /mL screen . PSA ≥4.0 ≤10.0 ng/mL screen prostate malignancy rule satisfaction urologist . Bladder postvoid residual ( PVR ) ≥150 mL ultrasound determination screen . History follow pelvic condition : Pelvic surgery pelvic procedure , include radical prostatectomy , pelvic surgery removal malignancy , bowel resection Pelvic radiotherapy Any pelvic surgical procedure urinary tract , include minimally invasive BPHLUTS therapy penile implant surgery Lower urinary tract malignancy trauma Lower urinary tract instrumentation ( include prostate biopsy ) within 30 day screen . History urinary retention lower urinary tract ( bladder ) stone within 6 month screen . History urethral obstruction due stricture , valve , sclerosis , tumor screening . History follow treatment within indicated duration : Antiandrogens within 11 month screen Dutasteride within 5 month screen Finasteride within 2 month screen Any erectile dysfunction treatment previously currently Any overactive bladder treatment within 4 week screen Have diagnosis history prostate cancer screen . Current history malignancy screening ( except treatmentfree relapsefree ≥3 year screen ) . Clinical evidence history follow bladder condition : Underactive Bladder Detrusorsphincter dyssynergia ( contraction detrusor without sphincter relaxation ) Interstitial cystitis Clinical evidence follow urinary tract condition : Active urogenital infection Clinically significant microscopic hematuria determine urologist History significant renal insufficiency meeting either following : Receiving renal dialysis Creatinine clearance ( CLcr ) &lt; 30 mL/minute Clinical evidence severe hepatic impairment Aspartate Transaminase ( AST ) Alanine Transaminase ( ALT ) &gt; 3 time upper limit normal range . History follow cardiac condition : Current history angina require treatment nitrate nitric oxide donor Current history unstable angina Positive cardiac stress test without document evidence subsequent , effective cardiac intervention ( e.g. , coronary angioplasty ) History follow coronary condition within 90 day screen : Myocardial infarction Coronary artery bypass graft surgery Percutaneous coronary intervention ( example , angioplasty stent placement ) Any evidence history heart failure ( New York Heart Association [ NYHA ] ≥ Class III ) . Currently receive alpha1 blocker therapy treatment hypertension . Current history follow symptom : Symptoms associate orthostasis ( e.g. , recurrent episode dizziness , lightheadedness , loss consciousness , syncope ) Causeless fall within 1 year screen Blood pressurerelated finding follow screening : Systolic blood pressure &gt; 160 &lt; 90 millimeter mercury ( mm Hg ) Diastolic blood pressure &gt; 100 &lt; 50 mm Hg Malignant hypertension Uncontrolled arrhythmia</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>